ARTL vs ASBP

Artelo Biosciences, Inc. vs Aspire Biopharma Holdings, Inc. — Valuation Comparison 2026

ARTL

Biotechnology
Artelo Biosciences, Inc.
Quality
3.9
out of 10
Value Trap
12
SAFE
Price
$1.46
Last close
Models
7/13
Active
VS

ASBP

Biotechnology
Aspire Biopharma Holdings, Inc.
Quality
4.6
out of 10
Value Trap
22
SAFE
Price
$5.53
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType ARTL Fair ValueARTL Upside ASBP Fair ValueASBP Upside
Bayesian DCF Intrinsic $2.56 +75.3% $3.92 -29.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $3.99 +173.1%
PWERM Option-Based $3.76 +157.7% $7.61 +37.6%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ARTL vs ASBP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ARTL vs ASBP — Which Stock Is More Undervalued?

ASBP scores higher with a 4.6/10 quality rating vs ARTL's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Artelo Biosciences, Inc. (ARTL) and Aspire Biopharma Holdings, Inc. (ASBP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ARTL currently trades at $1.46 with a QOC of 3.9/10, while ASBP trades at $5.53 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).